StockTipsArenaBeta

BUY Krishna Institute of Medical Sciences Limited — Rakesh Bansal

BUYKrishna Institute of Medical Sciences Limited

byRakesh BansalHorizon: NA (inferred Swing (≤2wk))24 Sept 2026via CNBC Awaaz.

Entry₹803.6Inferred
Target₹831
Total upside +3.41%
Stop loss₹785-2.31% risk
CMP₹805.2Just now
Active+0.20%+3.20%upside left 14d left
Follow Rakesh Bansal for new calls(35% target hit, 91 closed calls)Get alertsWatch KIMS for new buy/sell callsGet alertsSee 255 other Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 24 Sept, 12:23 pm IST
4 supporting2 neutral0 opposing
Supports the BUY call (4)

MACD above its signal line — bullish momentum

Technicals · macd·24 Sept · today

2 advisors have active short-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · adjacent horizon·17 Sept · 6d ago

KIMS enters O&M agreement to manage 183-bed Trust Hospital in Kakinada, Andhra Pradesh

NewsCnbc-Tv18·10 Sept · 2w ago

(opens in new tab)

Krishna Institute of Medical Sciences Ltd entered into an Operations and Management Agreement with Sarvottam Health Care Private Limited.

BSE · Company Update·10 Sept · 2w ago

(opens in new tab)
Neutral / worth noting (2)

KIMS Hospitals Promoters Pledge 6.66% Equity

NewsGoogle News·23 Sept · yesterday

(opens in new tab)

KIMS promoters pledge 6.66% stake to Catalyst Trusteeship

NewsGoogle News·23 Sept · yesterday

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.